“In terms of UMass Medical science impacting the world, it’s changing the world.”

Michael P. Czech, PhD is the founding chair of the Program in Molecular Medicine, University of Massachusetts Medical School.
Excellence in everything we do.

The University of Massachusetts Medical School has been called the “jewel in the crown” of our university and a “utopia for science.” As Chancellor, it is a great privilege to introduce you to the Commonwealth’s first and only public medical school.

At UMass Medical School, we’re bullish on the future of medical education, biomedical research and patient care because we witness excellence on our campus every day. Founded just half a century ago, we’ve grown into a dynamic, highly-ranked institution with a powerful impact that begins in Worcester, extends throughout all regions of the state and, now, reaches around the globe.

World-class faculty in our three graduate schools educate future physicians, nurses and scientists in a uniquely collaborative culture. Already among the most entrepreneurial medical schools in the nation, we endeavor to improve the human condition by focusing on initiatives that accelerate discovery, innovation and translation.

Excellence is our benchmark; service is our hallmark; and we are making our mark in Massachusetts and beyond. We invite you to learn more about UMass Medical School and are confident you’ll discover we’re here for a reason.
UMASS MEDICAL SCHOOL

Research that expands

- **$280 million in research funding** (FY16) places UMass Medical School in the top 2% of all NIH-funded institutions

- **Our world-class faculty are making seminal discoveries** in RNA, gene therapy and neuroscience, impacting diseases including ALS, cancer, diabetes, HIV and global & community health

- **A Nobel Laureate**, Breakthrough Prize recipient, Lasker Award winner, multiple Howard Hughes Medical Institute investigators and seven members of the National Academies lead research teams on our Worcester campus
$280 million in research funding (FY16)
$520 million
annual entrepreneurial & misc. revenue
Innovation that excites

- **Most entrepreneurial medical school in the U.S.**
  with $520 million/year in entrepreneurial & misc. revenue (5 year average)
  (compared to national average $29 million/year)

- **187 licenses with 109 companies**

- **396 U.S. patents, 594 worldwide patents**, plus 850+ patent applications in process

- **$33+ million in annual licensing revenue**, ranking #14 in the U.S.

- **Commonwealth Medicine** is the medical school's health care consulting division, charged with increasing the value and quality of public health expenditures in 20 states and 27 countries, while increasing access to at-risk and underserved populations

- **MassBiologics**, with locations in Boston and Fall River, is the only publicly owned, non-profit FDA-licensed manufacturer of vaccines and biologics, with a focus on solving unmet public health needs
UMASS MEDICAL SCHOOL

Academics that excel

- **Top 1%** in student satisfaction *(AAMC)*
- **Top 10% of medical schools** for primary care *(U.S. News & World Report)*
- **Most affordable** medical school in the Northeast
- **More than half our graduates practice primary care;** 62% stay in Massachusetts
- **1,200 students in three graduate schools** - the School of Medicine, Graduate School of Biomedical Sciences and the Graduate School of Nursing
- **Recent initiatives** include class expansion to accept out-of-state students, new regional campus
Top 1% in student satisfaction (AAMC)
“UMass Medical School has proven itself to be an invaluable and enthusiastic partner. Their expertise and collaborative spirit have helped to keep Voyager at the forefront of gene therapy discovery and therapeutic development.”

Steven Paul, M.D.,
President & CEO
Voyager Therapeutics

“UMass Medical School holds a special place in our commonwealth.”

Governor Charlie Baker

“The UMMS research enterprise is at the forefront of a revolution in scientific discovery that is unlocking the power of the human genome to develop new and innovative therapies to treat disease.”

Craig C. Mello, PhD,
Nobel Laureate
UMass Medical School